- NervGen Pharma press release (OTCQX:NGENF): FY GAAP EPS of -$0.39.
- NervGen had cash and investments of $22.5 million as of December 31, 2022,
- Research and development expenses were $16.6 million for the year ended December 31, 2022, compared to $6.9 million for the year ended December 31, 2021.
- General and administrative expenses were $6.4 million for the year ended December 31, 2022, compared to $5.9 million for the year ended December 31, 2021.